Shanghai Junshi Biosciences Balance Sheet Health
Financial Health criteria checks 4/6
Shanghai Junshi Biosciences has a total shareholder equity of CN¥6.3B and total debt of CN¥3.5B, which brings its debt-to-equity ratio to 56%. Its total assets and total liabilities are CN¥11.7B and CN¥5.4B respectively.
Key information
55.98%
Debt to equity ratio
CN¥3.52b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥3.27b |
| Equity | CN¥6.30b |
| Total liabilities | CN¥5.39b |
| Total assets | CN¥11.69b |
Recent financial health updates
Here's Why Shanghai Junshi Biosciences (HKG:1877) Can Afford Some Debt
Nov 20
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Sep 30Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?
Jun 28Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Mar 22Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Dec 17Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?
Sep 05Recent updates
Here's Why Shanghai Junshi Biosciences (HKG:1877) Can Afford Some Debt
Nov 20Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 29% Below Their Intrinsic Value Estimate
Oct 06Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jul 28Bullish: Analysts Just Made A Notable Upgrade To Their Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Forecasts
May 16Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement
Mar 03Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Oct 14Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Sep 30Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors
Aug 29Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?
Jun 28Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth
May 06Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Mar 22Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%
Jan 26Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Dec 17Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?
Nov 20Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?
Sep 05Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
May 22Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate
May 01Financial Position Analysis
Short Term Liabilities: 1877's short term assets (CN¥4.4B) exceed its short term liabilities (CN¥2.7B).
Long Term Liabilities: 1877's short term assets (CN¥4.4B) exceed its long term liabilities (CN¥2.6B).
Debt to Equity History and Analysis
Debt Level: 1877's net debt to equity ratio (4%) is considered satisfactory.
Reducing Debt: 1877's debt to equity ratio has increased from 13% to 56% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1877 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1877 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 00:53 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Junshi Biosciences Co., Ltd. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Congmin Yuan | Citic Securities Co., Ltd. |
| Wangbin Zhou | Citigroup Inc |